NIH #R01CA296335
The Role of EP300 Mutations in Bladder Cancer Pathogenesis and Drug Response
Active
- Amount
- $500K–$600K
- Period
- 2025-01-01 → 2029-12-31
- PIs
- 2
Awarded at SLOAN-KETTERING INST CAN RESEARCH
Full Professor(heuristic)
Bladder and Urothelial Cancer Treatments · Surgery
Compare more Surgery professors.
h-index56
i10-index134
Publications524
Citations25,318
Grants
4 total · 2 active
NIH #R01CA288692
HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma
Active
- Amount
- $500K–$600K
- Period
- 2024-04-01 → 2029-03-31
- PIs
- 3
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #R21CA267518
Combining BET protein inhibitors with radiation in HPV oropharyngeal cancer
- Amount
- $200K–$300K
- Period
- 2022-12-08 → 2024-11-30
- PIs
- 1
Awarded at UNIVERSITY OF WISCONSIN-MADISON
Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →
Recent Public Signals
- New paper: Supplementary Data from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer2026-06-17
- New NIH award: The Role of EP300 Mutations in Bladder Cancer Pathogenesis and Drug Response2025-01-01
- New NIH award: HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma2024-04-01
Are you this professor?
No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.
Data Freshness
- Publications as of 2026-07-09
- Grants as of 2026-08-28
Data may not be current
Find elsewhere
ORCID: 0000-0002-5093-6099